- Home
- ENTA vs MX Comparison
ENTA vs MX Comparison
Compare ENTA & MX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- MX
- Stock Information
- Founded
- ENTA 1995
- MX 2003
- Country
- ENTA United States
- MX South Korea
- Employees
- ENTA N/A
- MX N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- MX Semiconductors
- Sector
- ENTA Health Care
- MX Technology
- Exchange
- ENTA Nasdaq
- MX Nasdaq
- Market Cap
- ENTA 154.0M
- MX 142.1M
- IPO Year
- ENTA 2013
- MX N/A
- Fundamental
- Price
- ENTA $5.59
- MX $3.44
- Analyst Decision
- ENTA Buy
- MX Strong Buy
- Analyst Count
- ENTA 4
- MX 2
- Target Price
- ENTA $17.25
- MX $7.00
- AVG Volume (30 Days)
- ENTA 228.9K
- MX 286.5K
- Earning Date
- ENTA 05-05-2025
- MX 03-12-2025
- Dividend Yield
- ENTA N/A
- MX N/A
- EPS Growth
- ENTA N/A
- MX N/A
- EPS
- ENTA N/A
- MX N/A
- Revenue
- ENTA $66,590,999.00
- MX $231,737,000.00
- Revenue This Year
- ENTA N/A
- MX $12.64
- Revenue Next Year
- ENTA N/A
- MX N/A
- P/E Ratio
- ENTA N/A
- MX N/A
- Revenue Growth
- ENTA N/A
- MX 0.73
- 52 Week Low
- ENTA $4.71
- MX $3.33
- 52 Week High
- ENTA $17.80
- MX $5.98
- Technical
- Relative Strength Index (RSI)
- ENTA 31.66
- MX 30.85
- Support Level
- ENTA $5.65
- MX $3.76
- Resistance Level
- ENTA $5.96
- MX $3.98
- Average True Range (ATR)
- ENTA 0.36
- MX 0.25
- MACD
- ENTA -0.15
- MX -0.04
- Stochastic Oscillator
- ENTA 4.77
- MX 8.75
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.